annual cash & cash equivalents:
$2.49B-$241.80M(-8.86%)Summary
- As of today (June 4, 2025), REGN annual cash & cash equivalents is $2.49 billion, with the most recent change of -$241.80 million (-8.86%) on December 31, 2024.
- During the last 3 years, REGN annual cash & cash equivalents has fallen by -$397.40 million (-13.77%).
- REGN annual cash & cash equivalents is now -19.89% below its all-time high of $3.11 billion, reached on December 31, 2022.
Performance
REGN Cash and cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly cash & cash equivalents:
$3.09B+$602.00M(+24.19%)Summary
- As of today (June 4, 2025), REGN quarterly cash & cash equivalents is $3.09 billion, with the most recent change of +$602.00 million (+24.19%) on March 31, 2025.
- Over the past year, REGN quarterly cash & cash equivalents has increased by +$488.20 million (+18.76%).
- REGN quarterly cash & cash equivalents is now -21.09% below its all-time high of $3.92 billion, reached on March 31, 2023.
Performance
REGN quarterly cash & cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash and cash equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
REGN Cash and cash equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -8.9% | +18.8% |
| 3 y3 years | -13.8% | -7.6% |
| 5 y5 years | +53.8% | +39.9% |
REGN Cash and cash equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -19.9% | at low | -21.1% | +60.9% |
| 5 y | 5-year | -19.9% | +53.8% | -21.1% | +114.9% |
| alltime | all time | -19.9% | >+9999.0% | -21.1% | >+9999.0% |
REGN Cash and cash equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2025 | - | $3.09B(+24.2%) |
| Dec 2024 | $2.49B(-8.9%) | $2.49B(+23.7%) |
| Sep 2024 | - | $2.01B(+4.7%) |
| Jun 2024 | - | $1.92B(-26.2%) |
| Mar 2024 | - | $2.60B(-4.7%) |
| Dec 2023 | $2.73B(-12.1%) | $2.73B(+26.8%) |
| Sep 2023 | - | $2.15B(+11.1%) |
| Jun 2023 | - | $1.94B(-50.5%) |
| Mar 2023 | - | $3.92B(+26.1%) |
| Dec 2022 | $3.11B(+7.6%) | $3.11B(-11.0%) |
| Sep 2022 | - | $3.49B(+2.8%) |
| Jun 2022 | - | $3.40B(+1.5%) |
| Mar 2022 | - | $3.35B(+15.9%) |
| Dec 2021 | $2.89B(+31.5%) | $2.89B(-15.9%) |
| Sep 2021 | - | $3.43B(+65.6%) |
| Jun 2021 | - | $2.07B(+44.1%) |
| Mar 2021 | - | $1.44B(-34.5%) |
| Dec 2020 | $2.19B(+35.6%) | $2.19B(+39.5%) |
| Sep 2020 | - | $1.57B(-21.0%) |
| Jun 2020 | - | $1.99B(-9.8%) |
| Mar 2020 | - | $2.21B(+36.5%) |
| Dec 2019 | $1.62B(+10.2%) | $1.62B(+16.8%) |
| Sep 2019 | - | $1.38B(+32.5%) |
| Jun 2019 | - | $1.05B(-38.8%) |
| Mar 2019 | - | $1.71B(+16.4%) |
| Dec 2018 | $1.47B(+80.6%) | $1.47B(+34.9%) |
| Sep 2018 | - | $1.09B(+18.5%) |
| Jun 2018 | - | $917.88M(-10.0%) |
| Mar 2018 | - | $1.02B(+25.4%) |
| Dec 2017 | $812.70M(+51.8%) | $812.70M(+2.6%) |
| Sep 2017 | - | $792.07M(+6.4%) |
| Jun 2017 | - | $744.31M(-8.3%) |
| Mar 2017 | - | $811.77M(+51.7%) |
| Dec 2016 | $535.20M(-33.9%) | $535.20M(-41.8%) |
| Sep 2016 | - | $920.36M(+42.4%) |
| Jun 2016 | - | $646.51M(+7.0%) |
| Mar 2016 | - | $604.21M(-25.3%) |
| Dec 2015 | $809.10M(+24.7%) | $809.10M(+23.6%) |
| Sep 2015 | - | $654.59M(+67.6%) |
| Jun 2015 | - | $390.55M(-23.1%) |
| Mar 2015 | - | $507.91M(-21.7%) |
| Dec 2014 | $648.72M(+21.1%) | $648.72M(+0.3%) |
| Sep 2014 | - | $646.55M(+7.7%) |
| Jun 2014 | - | $600.13M(+29.9%) |
| Mar 2014 | - | $461.86M(-13.8%) |
| Dec 2013 | $535.61M(+132.6%) | $535.61M(+103.5%) |
| Sep 2013 | - | $263.21M(-31.0%) |
| Jun 2013 | - | $381.68M(+111.6%) |
| Mar 2013 | - | $180.36M(-21.7%) |
| Dec 2012 | $230.28M(-52.4%) | $230.28M(+93.5%) |
| Sep 2012 | - | $119.00M(-30.8%) |
| Jun 2012 | - | $171.94M(-56.4%) |
| Mar 2012 | - | $394.58M(-18.4%) |
| Dec 2011 | $483.61M(+329.6%) | $483.61M(+134.3%) |
| Sep 2011 | - | $206.40M(-18.8%) |
| Jun 2011 | - | $254.31M(+87.9%) |
| Mar 2011 | - | $135.38M(+20.3%) |
| Dec 2010 | $112.57M(-45.6%) | $112.57M(-65.4%) |
| Sep 2010 | - | $325.29M(+190.4%) |
| Jun 2010 | - | $112.00M(-4.5%) |
| Mar 2010 | - | $117.31M(-43.3%) |
| Dec 2009 | $207.07M(-16.4%) | $207.07M(-17.3%) |
| Sep 2009 | - | $250.32M(-7.8%) |
| Jun 2009 | - | $271.47M(+36.3%) |
| Mar 2009 | - | $199.10M(-19.7%) |
| Dec 2008 | $247.80M | $247.80M(-21.3%) |
| Sep 2008 | - | $314.68M(+7.7%) |
| Jun 2008 | - | $292.13M(-43.9%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2008 | - | $520.88M(+4.4%) |
| Dec 2007 | $498.93M(+109.7%) | $498.93M(+412.2%) |
| Sep 2007 | - | $97.42M(-11.2%) |
| Jun 2007 | - | $109.64M(-29.9%) |
| Mar 2007 | - | $156.48M(-34.2%) |
| Dec 2006 | $237.88M(+28.9%) | $237.88M(+41.9%) |
| Sep 2006 | - | $167.66M(+45.8%) |
| Jun 2006 | - | $114.96M(-37.0%) |
| Mar 2006 | - | $182.33M(-1.2%) |
| Dec 2005 | $184.51M(+93.8%) | $184.51M(+4.8%) |
| Sep 2005 | - | $176.09M(+21.3%) |
| Jun 2005 | - | $145.20M(-1.8%) |
| Mar 2005 | - | $147.82M(+55.2%) |
| Dec 2004 | $95.23M(-19.5%) | $95.23M(-9.3%) |
| Sep 2004 | - | $105.05M(-14.5%) |
| Jun 2004 | - | $122.83M(-29.4%) |
| Mar 2004 | - | $174.03M(+47.1%) |
| Dec 2003 | $118.28M(+47.7%) | $118.28M(-60.4%) |
| Sep 2003 | - | $298.62M(+130.3%) |
| Jun 2003 | - | $129.66M(-32.3%) |
| Mar 2003 | - | $191.59M(+139.3%) |
| Dec 2002 | $80.08M(-67.6%) | $80.08M(+6.0%) |
| Sep 2002 | - | $75.57M(+8.9%) |
| Jun 2002 | - | $69.37M(-48.8%) |
| Mar 2002 | - | $135.47M(-45.2%) |
| Dec 2001 | $247.39M(+698.6%) | $247.39M(+147.5%) |
| Sep 2001 | - | $99.97M(-30.1%) |
| Jun 2001 | - | $142.96M(-22.1%) |
| Mar 2001 | - | $183.62M(+492.7%) |
| Dec 2000 | $30.98M(+30.7%) | $30.98M(-37.6%) |
| Sep 2000 | - | $49.64M(-39.3%) |
| Jun 2000 | - | $81.75M(+565.0%) |
| Mar 2000 | - | $12.29M(-48.1%) |
| Dec 1999 | $23.70M(+19.7%) | $23.70M(+0.9%) |
| Sep 1999 | - | $23.50M(+14.1%) |
| Jun 1999 | - | $20.60M(-5.5%) |
| Mar 1999 | - | $21.80M(+10.1%) |
| Dec 1998 | $19.80M(-31.5%) | $19.80M(-12.4%) |
| Sep 1998 | - | $22.60M(+0.4%) |
| Jun 1998 | - | $22.50M(+16.6%) |
| Mar 1998 | - | $19.30M(-33.2%) |
| Dec 1997 | $28.90M(-16.2%) | $28.90M(-28.3%) |
| Sep 1997 | - | $40.30M(-21.6%) |
| Jun 1997 | - | $51.40M(+84.2%) |
| Mar 1997 | - | $27.90M(-19.1%) |
| Dec 1996 | $34.50M(+5.5%) | $34.50M(-8.0%) |
| Sep 1996 | - | $37.50M(-23.3%) |
| Jun 1996 | - | $48.90M(+310.9%) |
| Mar 1996 | - | $11.90M(-63.6%) |
| Dec 1995 | $32.70M(+38.6%) | $32.70M(+454.2%) |
| Sep 1995 | - | $5.90M(-64.9%) |
| Jun 1995 | - | $16.80M(+32.3%) |
| Mar 1995 | - | $12.70M(-46.2%) |
| Dec 1994 | $23.60M(+88.8%) | $23.60M(+54.2%) |
| Sep 1994 | - | $15.30M(-15.0%) |
| Jun 1994 | - | $18.00M(+125.0%) |
| Mar 1994 | - | $8.00M(-36.0%) |
| Dec 1993 | $12.50M(-23.8%) | $12.50M(-68.5%) |
| Sep 1993 | - | $39.70M(+402.5%) |
| Jun 1993 | - | $7.90M(-21.8%) |
| Mar 1993 | - | $10.10M(-38.4%) |
| Dec 1992 | $16.40M(-37.4%) | $16.40M(-14.6%) |
| Sep 1992 | - | $19.20M(-12.7%) |
| Jun 1992 | - | $22.00M(-11.6%) |
| Mar 1992 | - | $24.90M(-5.0%) |
| Dec 1991 | $26.20M(+20.2%) | $26.20M(-25.1%) |
| Sep 1991 | - | $35.00M(-10.7%) |
| Jun 1991 | - | $39.20M(+79.8%) |
| Dec 1990 | $21.80M | $21.80M |
FAQ
- What is Regeneron Pharmaceuticals annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Regeneron Pharmaceuticals?
- What is Regeneron Pharmaceuticals annual cash & cash equivalents year-on-year change?
- What is Regeneron Pharmaceuticals quarterly cash & cash equivalents?
- What is the all time high quarterly cash & cash equivalents for Regeneron Pharmaceuticals?
- What is Regeneron Pharmaceuticals quarterly cash & cash equivalents year-on-year change?
What is Regeneron Pharmaceuticals annual cash & cash equivalents?
The current annual cash & cash equivalents of REGN is $2.49B
What is the all time high annual cash & cash equivalents for Regeneron Pharmaceuticals?
Regeneron Pharmaceuticals all-time high annual cash & cash equivalents is $3.11B
What is Regeneron Pharmaceuticals annual cash & cash equivalents year-on-year change?
Over the past year, REGN annual cash & cash equivalents has changed by -$241.80M (-8.86%)
What is Regeneron Pharmaceuticals quarterly cash & cash equivalents?
The current quarterly cash & cash equivalents of REGN is $3.09B
What is the all time high quarterly cash & cash equivalents for Regeneron Pharmaceuticals?
Regeneron Pharmaceuticals all-time high quarterly cash & cash equivalents is $3.92B
What is Regeneron Pharmaceuticals quarterly cash & cash equivalents year-on-year change?
Over the past year, REGN quarterly cash & cash equivalents has changed by +$488.20M (+18.76%)